The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date. / Bruinsma, Sophie M; Zhang, Liying; Roobol, Monique J; Bangma, Chris H; Steyerberg, Ewout W; Nieboer, Daan; Van Hemelrijck, Mieke; Bjartell, Anders (Medarbetare); Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

I: BJU International, Vol. 121, Nr. 5, 05.2018, s. 737-744.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Bruinsma, SM, Zhang, L, Roobol, MJ, Bangma, CH, Steyerberg, EW, Nieboer, D, Van Hemelrijck, M, Bjartell, A & Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium 2018, 'The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date', BJU International, vol. 121, nr. 5, s. 737-744. https://doi.org/10.1111/bju.14106

APA

Bruinsma, S. M., Zhang, L., Roobol, M. J., Bangma, C. H., Steyerberg, E. W., Nieboer, D., ... Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium (2018). The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 121(5), 737-744. https://doi.org/10.1111/bju.14106

CBE

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M, Bjartell A, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. 2018. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International. 121(5):737-744. https://doi.org/10.1111/bju.14106

MLA

Vancouver

Author

Bruinsma, Sophie M ; Zhang, Liying ; Roobol, Monique J ; Bangma, Chris H ; Steyerberg, Ewout W ; Nieboer, Daan ; Van Hemelrijck, Mieke ; Bjartell, Anders ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. / The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date. I: BJU International. 2018 ; Vol. 121, Nr. 5. s. 737-744.

RIS

TY - JOUR

T1 - The Movember Foundation's GAP3 cohort

T2 - a profile of the largest global prostate cancer active surveillance database to date

AU - Bruinsma, Sophie M

AU - Zhang, Liying

AU - Roobol, Monique J

AU - Bangma, Chris H

AU - Steyerberg, Ewout W

AU - Nieboer, Daan

AU - Van Hemelrijck, Mieke

AU - Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

A2 - Bjartell, Anders

N1 - © 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

PY - 2018/5

Y1 - 2018/5

N2 - OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database.PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time.RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing.CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

AB - OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database.PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time.RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing.CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

KW - Aged

KW - Aged, 80 and over

KW - Charities/organization & administration

KW - Cohort Studies

KW - Databases, Factual

KW - Disease Progression

KW - Early Detection of Cancer

KW - Global Health

KW - Humans

KW - Male

KW - Men's Health

KW - Middle Aged

KW - Prognosis

KW - Prostatic Neoplasms/epidemiology

KW - Public Health Surveillance

KW - Risk Assessment

KW - Time Factors

KW - Time-to-Treatment

KW - Watchful Waiting

U2 - 10.1111/bju.14106

DO - 10.1111/bju.14106

M3 - Article

VL - 121

SP - 737

EP - 744

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -